Our findings suggest that MARCH5 participates in the pathological cardiac hypertrophy by regulating the Akt/mTOR/Gsk‐3β/GATA4 pathway, positioning it as a promising therapeutic target for cardiac hypertrophy. Here, MARCHF5 is linked to cardiac hypertrophy.